Combined administration of the GPVI-Fc fusion protein Revacept with low-dose thrombolysis in the treatment of stroke.

about

Anti-GPVI Fab SAR264565 effectively blocks GPVI function in ex vivo human platelets under arterial shear in a perfusion chamber.Design, development and characterization of ACT017, a humanized Fab that blocks platelet's glycoprotein VI function without causing bleeding risks.

P2860

Q32177061-4B30292C-4522-4842-AE7A-48024B69A677 Q33442579-0D174BC1-91A4-4B61-A66F-38646F1D4883

P2860

Combined administration of the GPVI-Fc fusion protein Revacept with low-dose thrombolysis in the treatment of stroke.

Item

http://www.wikidata.org/entity/Q41516753

description

2016 nî lūn-bûn

@nan

2016年の論文

@ja

2016年論文

@yue

2016年論文

@zh-hant

2016年論文

@zh-hk

2016年論文

@zh-mo

2016年論文

@zh-tw

2016年论文

@wuu

2016年论文

@zh

2016年论文

@zh-cn

name

Combined administration of the ...... is in the treatment of stroke.

@en

type

Item

label

Combined administration of the ...... is in the treatment of stroke.

@en

prefLabel

Combined administration of the ...... is in the treatment of stroke.

@en

P1476

Combined administration of the ...... is in the treatment of stroke.

@en

P2093

Andreas Reimann

http://www.w3.org/2001/XMLSchema#string

Götz Münch

http://www.w3.org/2001/XMLSchema#string

Hans-Peter Holthoff

http://www.w3.org/2001/XMLSchema#string

Julia Fassbender

http://www.w3.org/2001/XMLSchema#string

Martin Ungerer

http://www.w3.org/2001/XMLSchema#string

Meinrad Gawaz

http://www.w3.org/2001/XMLSchema#string

Silvia Goebel

http://www.w3.org/2001/XMLSchema#string

Zhongmin Li

http://www.w3.org/2001/XMLSchema#string

P2860

Heart Disease and Stroke Statistics--2013 Update: A Report From the American Heart Association

Platelet-collagen interaction: is GPVI the central receptor?

The GPVI-Fc fusion protein Revacept reduces thrombus formation and improves vascular dysfunction in atherosclerosis without any impact on bleeding times

Thrombolysis with alteplase 3 to 4.5 hours after acute ischemic stroke

Tissue plasminogen activator for acute ischemic stroke

Effects of recombinant tissue plasminogen activator after intraluminal thread occlusion in mice: role of hemodynamic alterations.

Aggravation of focal cerebral ischemia by tissue plasminogen activator is reversed by 3-hydroxy-3-methylglutaryl coenzyme A reductase inhibitor but does not depend on endothelial NO synthase.

Mouse model of in situ thromboembolic stroke and reperfusion.

The GPVI-Fc fusion protein Revacept improves cerebral infarct volume and functional outcome in stroke

An activated protein C analog with reduced anticoagulant activity extends the therapeutic window of tissue plasminogen activator for ischemic stroke in rodents.

P304

e10-e16

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.5301/HEARTINT.5000229

http://www.w3.org/2001/XMLSchema#string

P433

http://www.w3.org/2001/XMLSchema#string

P478

http://www.w3.org/2001/XMLSchema#string

P577

2016-01-01T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P698

27924212

http://www.w3.org/2001/XMLSchema#string

P921

thrombolysis

P932

5072291

http://www.w3.org/2001/XMLSchema#string

Combined administration of the GPVI-Fc fusion protein Revacept with low-dose thrombolysis in the treatment of stroke.

about

P2860

P2860

Combined administration of the GPVI-Fc fusion protein Revacept with low-dose thrombolysis in the treatment of stroke.

description

name

type

label

prefLabel

P1433

P1476

P2093

P2860

P304

P31

P356

P433

P478

P577

P698

P921

P932

P356

P1433

P1476

P2093

P2860

P304

P31

P356

P433

P478

P577

P698

P921

P932